Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study
Authors' conclusion
Treatment with alirocumab in addition to high-intensity statin therapy might produce a greater PB regression in patients with familial hypercholesterolemia with higher baseline PB and in those with larger unstable core.
Study context
- Population
- Familial hypercholesterolemia without clinical atherosclerotic CVD51.9% women
- Participants
- 104 participants
- Outcome
- Change in coronary plaque burden (PB) on coronary CT angiography and plaque characteristics associated with greater PB reduction
- Follow-up
- 78 weeks
Methodological detailsopen-label, multicenter
- Open-label
- Multicenter
Main finding
As reported in the abstract
Global coronary PB
Global coronary plaque burden (PB) from 34.6% (32.5%-36.8%) at entry to 30.4% (27.4%-33.4%) at follow-up
−4.6%
−7.7% to −1.9%P<0.001
Further findings
Unstable core (fibro-fatty+necrotic plaque), %
- Decrease in % unstable core from 14.1 [7.9-22.3] to 8.0 [6.4-10.6]
- −6.6%; P<0.001
Baseline plaque characteristics associated with PB regression
- Greater PB, β
- 0.36 [0.13-0.59]; P=0.002
- Higher proportion of unstable core, β
- 0.15 [0.08-0.22]; P<0.001
Original publication
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circ Cardiovasc Imaging. Published 11 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →